Text and Data Mining valid from 2017-11-01
Received: 19 June 2017
Accepted: 10 October 2017
First Online: 8 November 2017
: G.P. and M.D.L. are co-founders and members of the Board of Directors of Holostem Terapie Avanzate (HTA), s.r.l, Modena, Italy; Chiesi Farmaceutici S.p.A. (a co-founder of HTA), holds an Orphan Drug Medicinal Product designation (EU/3/15/1465) for the transgenic cultures used in this paper.